Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q4 2021
0
Period ended Dec 31, 2021
Change on a year earlier
–
History
4 quarters
Since Q1 2021
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 0 | – | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 153 | – | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2021 | Mar 31, 2021 | 153 | – | Form 10-Q (filed 2022-05-05) ↗ |
Cite this data
StockData. (2026). Merck Bayer AG (Adempas & Verquvo sGC Cardiovascular Alliance) — Intangible asset amortization in Cost of Sales ($M) ($M), quarterly Q1 2021–Q4 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_bayer_amort
See every metric in the Merck KPI table. Data updated Oct 26, 2026.